25
Participants
Start Date
November 15, 2024
Primary Completion Date
April 30, 2026
Study Completion Date
May 31, 2027
Lorlatinib 100 mg
Eligible patients will be registered to receive oral lorlatinib 100mg qd for 6-8 weeks each during the neoadjuvant therapy phase
Hunan Cancer Hospital
OTHER
Liaoning Cancer Hospital & Institute
OTHER
Air Force Military Medical University, China
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Peking University People's Hospital
OTHER